Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02559206

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Irritable Bowel Syndrome With Constipation Clinical Trial

Official title:
A Phase 2b, Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel-group, Dose-range-finding Study of Two Delayed Release Formulations of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation

Clinical Trial Summary

The objectives of this study are to evaluate the safety, efficacy, and dose response of two delayed release formulations of linaclotide (DR; DR formulation 1 is DR1; DR formulation 2 is DR2) administered orally to patients with irritable bowel syndrome with constipation (IBS-C). Additional objectives include understanding how the two DR formulations compare with each other and with the FDA-approved 290 μg LINZESS® (the immediate release [IR] formulation of linaclotide).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02559206
Study type Interventional
Source Ironwood Pharmaceuticals, Inc.
Contact
Status Completed
Phase Phase 2
Start date October 22, 2015
Completion date September 30, 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT00730171 - An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Phase 3
Completed NCT00215566 - A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c Phase 2
Completed NCT00765999 - An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation Phase 3
Recruiting NCT05646186 - Personalized Dietary Intervention Based on Microbiome Analysis vs FODMAP Diet for Irritable Bowel Syndrome N/A
Completed NCT04026113 - Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC) Phase 3
Recruiting NCT05519683 - Home Transcutaneous Electrical Acustimulation (TEA) Phase 2/Phase 3
Active, not recruiting NCT04166058 - Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C Phase 3
Completed NCT04968652 - IBS-C Questionnaire Study
Completed NCT05164861 - Safety and Efficacy of Non-alcoholic Beverage Based on Kombucha in Patients With Constipations N/A
Completed NCT02590432 - An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation Phase 4
Terminated NCT02559817 - A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation Phase 2
Recruiting NCT05796388 - A Study of Virtual Reality and Linaclotide for IBS-C N/A
Completed NCT00380250 - Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation Phase 3
Completed NCT04647045 - An Evaluation of Cultured Milk Drink on Immune Status of Patients With Irritable Bowel Syndrome: Constipation Predominant N/A
Completed NCT03054506 - The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation N/A
Recruiting NCT04214470 - A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS
Not yet recruiting NCT06219707 - Electro-acupuncture for Irritable Bowel Syndrome With Constipation N/A
Recruiting NCT03596905 - Efficacy and Safety of Plecanatide in Children 6 to <18 Years of Age With Irritable Bowel Syndrome With Constipation (IBS-C) Phase 2
Completed NCT04132804 - Effect of Tai Chi as Treatment for IBS-C N/A
Completed NCT00938717 - Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) Phase 3